Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Luminex, One Lambda extend strategic collaboration
The partnership has resulted in the creation of new products that have made pre- and post-transplant diagnostics faster, and more cost-efficient. One Lambda has adopted Luminex’s xMAP technology
The partnership has resulted in the creation of new products that have made pre- and post-transplant diagnostics faster, and more cost-efficient. One Lambda has adopted Luminex’s xMAP technology
SQ109 is currently in Phase II clinical study in patients with pulmonary TB and based on the Phase 1 results achieved under its TB IND, Sequella will conduct
Selcia managing director Hans Fliri said that they can now offer pharmaceutical and biotech companies cost effective radiolabelling services to support both the pre-clinical and clinical development of
Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.
Emerflu was intended to be used for prophylaxis of influenza in an officially declared pandemic situation. Sanofi Pasteur has submitted the marketing authorisation application to the European Medicines
The product will be launched under Alapis international probiotic brand, which currently carries two products. Probi will start shipments in the second quarter of 2011 and the product
GSK said 90% of the share capital of MeiRui is to be acquired from Pagoda Pharmaceuticals and the remaining 10% from Allergon in a move to further expand
Safety, tolerability and pharmacokinetics of rVWF combined with rFVIII at a fixed ratio were investigated in the Phase 1 multicenter, international clinical study in 32 patients with type
TLC claims that ProFlow is an improved Prostaglandin E1 emulsion with extended shelf stability of more than two years, developed by TLC with its proprietary formulation, patented worldwide.
Perifosine is a novel, oral anticancer treatment that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway. The product works by interfering with membranes of cancer cells thereby